https://scholars.lib.ntu.edu.tw/handle/123456789/487346
標題: | Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study | 作者: | CHIA-CHI LIN CHIH-HUNG HSU CHAO-YUAN HUANG Keng H.-Y. YU-CHIEH TSAI KUO-HOW HUANG ANN-LII CHENG YEONG-SHIAU PU |
公開日期: | 2007 | 卷: | 18 | 期: | 4 | 起(迄)頁: | 487-491 | 來源出版物: | Anti-Cancer Drugs | 摘要: | Few treatment options are available for cisplatin-refractory urothelial carcinoma. We evaluated the efficacy and safety of a new regimen composed of gemcitabine and ifosfamide as a second-line salvage chemotherapy for the disease. The gemcitabine and ifosfamide regimen consists of gemcitabine 800 mg/m/day intravenously for 30 min on days 1, 8, and 15; ifosfamide 1500 mg/m/day intravenously for 24 h on days 8-10; and mesna 800 mg intravenously bolus before ifosfamide and 1500 mg/m/day intravenously for 24 h on days 8-11. Cycles are repeated every 28 days. Between 1998 and 2005, 23 patients (median age 66) unresponsive to cisplatin-based chemotherapy (n=10) or who had tumor progression within 6 months of a previous response to cisplatin-based therapy (n=13) were enrolled. The median interval between the two chemotherapy regimens was 1.8 months (range 0.9-5.6). In total, 82 treatment cycles (median 3, range 1-8) were given. The overall response rate was 22% (95% confidence interval 5-39) with one complete response and four partial responses. Twenty-one patients succumbed to the disease. The median progression-free survival and overall survival were 3.5 and 4.8 months, respectively. Grade 3 or 4 leukopenia and thrombocytopenia occurred in 10 and eight patients, respectively. One, two and two patients complicated with grade 3 vomiting, diarrhea and stomatitis were present, respectively. No grade 3 or 4 neurotoxicity or nephrotoxicity was seen in these patients. The gemcitabine and ifosfamide regimen has an acceptable toxicity profile, but shows insufficient clinical activity in patients with cisplatin-refractory urothelial carcinoma to warrant further testing. ? 2007 Lippincott Williams & Wilkins, Inc. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-34247593884&doi=10.1097%2fCAD.0b013e3280126603&partnerID=40&md5=33f980a7445c8957404f801fdc857331 https://scholars.lib.ntu.edu.tw/handle/123456789/487346 |
ISSN: | 0959-4973 | DOI: | 10.1097/CAD.0b013e3280126603 | SDG/關鍵字: | carboplatin; cisplatin; docetaxel; fluorouracil; folinic acid; gemcitabine; ifosfamide; mesna; methotrexate; oxaliplatin; paclitaxel; tamoxifen; vinblastine; alkylating agent; antineoplastic agent; antineoplastic antimetabolite; cisplatin; deoxycytidine; drug derivative; gemcitabine; ifosfamide; adult; aged; article; cancer chemotherapy; cancer survival; clinical article; clinical trial; combination chemotherapy; confidence interval; continuous infusion; drug dose reduction; drug efficacy; drug response; drug safety; female; human; male; metastasis; multiple cycle treatment; phase 2 clinical trial; priority journal; salvage therapy; tumor growth; unspecified side effect; urogenital tract tumor; bladder tumor; chemically induced disorder; drug resistance; hematologic disease; metastasis; pathology; phase 1 clinical trial; survival; urothelium; Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Deoxycytidine; Drug Resistance, Neoplasm; Female; Hematologic Diseases; Humans; Ifosfamide; Male; Neoplasm Metastasis; Survival Analysis; Urinary Bladder Neoplasms; Urothelium |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。